Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020

Chronic Human Pegivirus 2 without Hepatitis C Virus Co-infection

Kelly E. CollerComments to Author , Veronica Bruce, Michael Cassidy, Jeffrey Gersch, Matthew B. Frankel, Ana Vallari, Gavin Cloherty, John Hackett, Jennifer L. Evans, Kimberly Page, and George J. Dawson
Author affiliations: Abbott Laboratories, Abbott Park, Illinois, USA (K.E. Coller, M. Cassidy, J. Gersch, M.B. Frankel, A. Vallari, G. Cloherty, J. Hackett, Jr., G.J. Dawson); University of New Mexico, Albuquerque, New Mexico, USA (V. Bruce, K. Page); University of California San Francisco, San Francisco, California, USA (J.L. Evans)

Main Article

Table 5

Characteristics of findings in study of chronic HPgV-2 infection for participants with and without HCV co-infection in injection drug users in the San Francisco Bay area, California, USA*

Finding HCV negative, n = 3 HCV positive, n = 2 p value
Average HPgV-2, log10 copies/mL
NS2/3 3.26 3.21 0.11
5′ UTR
Average years injection drug use† 5.5 7.9 NA
Average age at detection of HPgV-2 RNA, y† 25.6 26.1 NA

*HCV, hepatitis C virus; HPgV-2, human pegivirus 2; NS, nonstructural protein.
†No p values available because of low number of samples.

Main Article

Page created: January 17, 2020
Page updated: January 17, 2020
Page reviewed: January 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.